Disclosure: The authors declare competing financial interests. Authors F.M.A.P., D.E.B., M.T., and W.P.P. are cofounders of Isomark LLC.
NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T1AM treatment
Article first published online: 29 MAY 2013
Copyright © 2013 The Obesity Society
Volume 21, Issue 12, pages 2538–2544, December 2013
How to Cite
Haviland, J.A., Reiland, H., Butz, D.E., Tonelli, M., Porter, W.P., Zucchi, R., Scanlan, T.S., Chiellini, G. and Assadi-Porter, F.M. (2013), NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T1AM treatment. Obesity, 21: 2538–2544. doi: 10.1002/oby.20391
Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author notes may be found in the online version of this article.
Funding agencies: This research was supported by the Rodale Foundation, the Farmers Advocating for Organics (FAFO) fund, grant R01 DC009018 from NIH, and the Wisconsin Institute of Discovery Grant (WID-135A039). This work was supported in part by funds from the following: the Rodale Foundation; the Farmers Advocating for Organics (FAFO) fund to W.P.P.; grants R01 DC009018 from NIH; the Wisconsin Institute of Discovery Grant (WID-135A039) to F.M.A.P. This study made use of the National Magnetic Resonance Facility at Madison, which is supported by NIH grants P41RR02301 (BRTP/ NCRR) and P41GM66326 (NIGMS). Additional equipment was purchased with funds from the University of Wisconsin, the NIH (RR02781, RR08438), the NSF (DMB-8415048, OIA-9977486, BIR-9214394), and the USDA.
- Issue published online: 3 DEC 2013
- Article first published online: 29 MAY 2013
- Accepted manuscript online: 20 MAR 2013 02:13AM EST
- Manuscript Accepted: 9 JAN 2013
- Manuscript Revised: 8 JAN 2013
- Manuscript Received: 8 NOV 2012
- The Rodale Foundation
- The Farmers Advocating for Organics (FAFO) fund. Grant Number: R01 DC009018 from NIH
- The Wisconsin Institute of Discovery Grant. Grant Number: WID-135A039
This article has been cited by:
- 13-iodothyronamine differentially modulates -2A-adrenergic receptor-mediated signaling, Journal of Molecular Endocrinology, 2015, 54, 3, 205, , , , , , , , , , , , , , ,
- 2Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists, Journal of Medicinal Chemistry, 2015, 58, 12, 5096, , , , , , , , , , , , , , ,
- 3Update on 3-iodothyronamine and its neurological and metabolic actions, Frontiers in Physiology, 2014, 5,, , ,
- 4Uptake and metabolic effects of 3-iodothyronamine in hepatocytes, Journal of Endocrinology, 2014, 221, 1, 101, , , , ,